Avidity Partners Management LP
- SEC CIK
- 0001791827
- Latest filing
- Aug 14, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Feb 14, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 61
- −20 vs. Q3 2024
- Portfolio value
- $1.00B
- −$957.2M (−48.8%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| DNTHDianthus Therapeutics, Inc. | COM | 2,873,000 | $62.6M | 6.2% | −44,231−1.5% | Reduced | History |
| BSXBoston Scientific Corp | Stock | 515,000 | $46.0M | 4.6% | −447,000−46.5% | Reduced | History |
| JANXJanux Therapeutics, Inc. | COM | 741,900 | $39.7M | 4.0% | +179,900+32.0% | Added | History |
| NTRANatera, Inc. | COM | 223,800 | $35.4M | 3.5% | −332,600−59.8% | Reduced | History |
| EXASExact Sciences Corp | COM | 603,011 | $33.9M | 3.4% | +15,011+2.6% | Added | History |
| ISRGIntuitive Surgical Inc | COM NEW | 64,800 | $33.8M | 3.4% | −83,400−56.3% | Reduced | History |
| CGONCG Oncology, Inc. | COM | 1,097,800 | $31.5M | 3.1% | −558,200−33.7% | Reduced | History |
| UNHUnitedHealth Group Inc | Stock | 60,000 | $30.4M | 3.0% | −27,400−31.4% | Reduced | History |
| NBIXNeurocrine Biosciences Inc | Stock | 220,400 | $30.1M | 3.0% | −239,600−52.1% | Reduced | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 1,126,700 | $29.0M | 2.9% | −246,300−17.9% | Reduced | History |
| JAZZJazz Pharmaceuticals plc | SHS USD | 234,500 | $28.9M | 2.9% | −196,500−45.6% | Reduced | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 666,200 | $27.5M | 2.7% | −64,904−8.9% | Reduced | History |
| ACHCAcadia Healthcare Company, Inc. | COM | 658,000 | $26.1M | 2.6% | −327,000−33.2% | Reduced | History |
| ARVNArvinas, Inc. | COM | 1,358,000 | $26.0M | 2.6% | −139,000−9.3% | Reduced | History |
| GKOSGLAUKOS Corp | COM | 170,000 | $25.5M | 2.5% | −174,900−50.7% | Reduced | History |
| DXCMDexcom Inc | COM | 318,000 | $24.7M | 2.5% | +78,000+32.5% | Added | History |
| TMOThermo Fisher Scientific Inc. | Stock | 44,600 | $23.2M | 2.3% | −24,000−35.0% | Reduced | History |
| HUMHumana Inc | Stock | 89,200 | $22.6M | 2.3% | −40,500−31.2% | Reduced | History |
| KYMRKymera Therapeutics, Inc. | COM | 500,000 | $20.1M | 2.0% | 00.0% | Unchanged | History |
| AVTRAvantor, Inc. | COM | 947,000 | $20.0M | 2.0% | −288,000−23.3% | Reduced | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 1,500,000 | $19.8M | 2.0% | −955,000−38.9% | Reduced | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 1,165,800 | $19.5M | 1.9% | −966,200−45.3% | Reduced | History |
| RVMDRevolution Medicines, Inc. | COM | 446,200 | $19.5M | 1.9% | −343,800−43.5% | Reduced | History |
| XENEXenon Pharmaceuticals Inc. | COM | 474,000 | $18.6M | 1.9% | −344,000−42.1% | Reduced | History |
| THCTenet Healthcare Corp | COM NEW | 137,000 | $17.3M | 1.7% | −116,000−45.8% | Reduced | History |
| INSMINSMED Inc | COM PAR $.01 | 232,800 | $16.1M | 1.6% | −359,200−60.7% | Reduced | History |
| AXSMAxsome Therapeutics, Inc. | COM | 188,000 | $15.9M | 1.6% | −108,100−36.5% | Reduced | History |
| BPMCBlueprint Medicines Corp | COM | 176,600 | $15.4M | 1.5% | −138,400−43.9% | Reduced | History |
| DHRDanaher Corp | Stock | 67,000 | $15.4M | 1.5% | −28,000−29.5% | Reduced | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 352,000 | $14.8M | 1.5% | −400,000−53.2% | Reduced | History |
| ILMNIllumina, Inc. | COM | 109,700 | $14.7M | 1.5% | −182,300−62.4% | Reduced | History |
| ABBVAbbVie Inc. | Stock | 80,700 | $14.3M | 1.4% | −19,300−19.3% | Reduced | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 1,053,300 | $13.2M | 1.3% | +304,300+40.6% | Added | History |
| BMYBristol Myers Squibb Co | Stock | 215,000 | $12.2M | 1.2% | −48,000−18.3% | Reduced | History |
| TMDXTransMedics Group, Inc. | COM | 192,400 | $12.0M | 1.2% | +164,800+597.1% | Added | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 1,390,100 | $11.3M | 1.1% | −414,393−23.0% | Reduced | History |
| SGRYSurgery Partners, Inc. | Stock | 514,200 | $10.9M | 1.1% | −312,800−37.8% | Reduced | History |
| ORICOric Pharmaceuticals, Inc. | COM | 1,265,200 | $10.2M | 1.0% | −181,919−12.6% | Reduced | History |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 354,000 | $9.10M | 0.9% | −535,700−60.2% | Reduced | History |
| INCYIncyte Corp | COM | 129,600 | $8.95M | 0.9% | −178,510−57.9% | Reduced | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 2,694,600 | $8.60M | 0.9% | −749,402−21.8% | Reduced | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 62,000 | $8.54M | 0.9% | −57,000−47.9% | Reduced | History |
| BHVNBiohaven Ltd. | COM | 222,900 | $8.33M | 0.8% | −242,100−52.1% | Reduced | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 97,000 | $8.10M | 0.8% | −136,000−58.4% | Reduced | History |
| IMUXImmunic, Inc. | COM | 7,966,400 | $7.97M | 0.8% | −299,600−3.6% | Reduced | History |
| CNTXContext Therapeutics Inc. | COM | 7,477,200 | $7.85M | 0.8% | +60,045+0.8% | Added | History |
| ORKAOruka Therapeutics, Inc. | COM | 352,124 | $6.83M | 0.7% | −438,802−55.5% | Reduced | History |
| REGNRegeneron Pharmaceuticals, Inc. | COM | 8,400 | $5.98M | 0.6% | +8,400 | New | History |
| BRKRBruker Corp | COM | 76,300 | $4.47M | 0.4% | +76,300 | New | History |
| VERAVera Therapeutics, Inc. | CL A | 100,000 | $4.23M | 0.4% | +100,000 | New | History |
| RGNXREGENXBIO Inc. | COM | 532,000 | $4.11M | 0.4% | −600,564−53.0% | Reduced | History |
| QUREuniQure N.V. | SHS | 222,000 | $3.92M | 0.4% | −451,618−67.0% | Reduced | History |
| KZRKezar Life Sciences, Inc. | COM | 502,600 | $3.38M | 0.3% | 00.0% | UnchangedConverted for a 1-for-10 split | History |
| KROSKeros Therapeutics, Inc. | COM | 210,000 | $3.32M | 0.3% | −83,200−28.4% | Reduced | History |
| AKROAkero Therapeutics, Inc. | COM | 82,000 | $2.28M | 0.2% | +82,000 | New | History |
| DYNDyne Therapeutics, Inc. | COM | 96,000 | $2.26M | 0.2% | −69,000−41.8% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 287,104 | $2.24M | 0.2% | −713,896−71.3% | Reduced | History |
| SCYXScynexis Inc | COM NEW | 1,228,910 | $1.49M | 0.1% | −219,818−15.2% | Reduced | History |
| KPTIKaryopharm Therapeutics Inc. | COM | 2,018,500 | $1.37M | 0.1% | 00.0% | Unchanged | History |
| HYPRHyperfine, Inc. | COM CL A | 1,188,178 | $1.05M | 0.1% | 00.0% | Unchanged | History |
| BLUEbluebird bio, Inc. | COM NEW | 81,555 | $680.2K | 0.1% | 00.0% | UnchangedConverted for a 1-for-20 split | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q3 2024 (24)
Positions held at the end of Q3 2024 that are gone from this filing.
| Security | Class | Shares in Q3 2024 | Value in Q3 2024 | % of portfolio in Q3 2024 | History |
|---|---|---|---|---|---|
| NMRANeumora Therapeutics, Inc. | COM | 1,800,000 | $23.8M | 1.2% | History |
| BMRNBiomarin Pharmaceutical Inc | COM | 320,000 | $22.5M | 1.1% | History |
| ARGXArgenx SE | SPONSORED ADR | 38,200 | $20.7M | 1.1% | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 430,900 | $18.9M | 1.0% | History |
| NGNENeurogene Inc. | COM | 425,041 | $17.8M | 0.9% | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 2,133,872 | $17.8M | 0.9% | History |
| BNTXBioNTech SE | SPONSORED ADS | 145,000 | $17.2M | 0.9% | History |
| ZTSZoetis Inc. | Stock | 71,000 | $13.9M | 0.7% | History |
| IMNMImmunome Inc. | COM | 873,891 | $12.8M | 0.7% | History |
| APGEApogee Therapeutics, Inc. | COM | 154,000 | $9.05M | 0.5% | History |
| PRVAPrivia Health Group, Inc. | COM | 466,800 | $8.50M | 0.4% | History |
| HELPHelus Pharma Inc. | COM NEW | 918,000 | $8.16M | 0.4% | History |
| ESTAEstablishment Labs Holdings Inc. | COM | 169,000 | $7.31M | 0.4% | History |
| CGEMCullinan Therapeutics, Inc. | COM | 425,000 | $7.11M | 0.4% | History |
| IMCRImmunocore Holdings plc | ADS | 200,000 | $6.23M | 0.3% | History |
| SNYSanofi | SPONSORED ADR | 100,000 | $5.76M | 0.3% | History |
| EDITEditas Medicine, Inc. | COM | 1,465,000 | $5.00M | 0.3% | History |
| IMVTImmunovant, Inc. | COM | 99,000 | $2.82M | 0.1% | History |
| ANROAlto Neuroscience, Inc. | COM SHS | 240,000 | $2.75M | 0.1% | History |
| PRMEPrime Medicine, Inc. | COM | 694,000 | $2.69M | 0.1% | History |
| SYRSSyros Pharmaceuticals, Inc. | COM NEW | 1,063,000 | $2.29M | 0.1% | History |
| TILInstil Bio, Inc. | COM NEW | 29,100 | $1.96M | 0.1% | History |
| PRLDPrelude Therapeutics Inc | COM | 890,000 | $1.84M | 0.1% | History |
| CMAXCareMax, Inc. | COMM STK | 21,200 | $36.0K | <0.1% | History |